Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of CD19 CAR T-Cell Therapy for the Treatment of Refractory Systemic Lupus Erythematosus: A Phase I Clinical Trial

NCT07432334 is registered in ClinicalTrials.gov with Vinmec Research Institute of Stem Cell and Gene Technology as lead sponsor.

NCT NCT07432334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07432334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of CD19 CAR T-Cell Therapy for the Treatment of Refractory Systemic Lupus Erythematosus: A Phase I Clinical Trial
Lead sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Phase
Phase 1
Overall status
Recruiting
Start date
March 1, 2026
Completion date
November 30, 2027
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory systemic lupus erythematosus